FDA-cleared. Quietly adopted. Nationally ready. KeyLift™ is about to get loud.
Amplio Spine, LLC signs Letter of Intent to acquire the FDA–cleared KeyLift™ Expandable Interlaminar Stabilization System (K232484) — comprising KeyLiftXS™ and KeyLiftXL™, the only minimally invasive platform in
KeyLift™ received FDA 510(k) clearance in late 2023 (K232484), with the first surgical implantation in
Surgeons, distributors, and media can learn more, request product information, or schedule interviews with the leadership team at www.ampliospine.com or by contacting [email protected].
A Category of One
Leading the company is
"This is not a me–too device, and this is not an incremental play," said
Built on Legacy. Led by Operators.
The KeyLift™ family was designed by the late
Joining the executive team as Chief Operating Officer and Co–Founder is
"This is the kind of platform you build a company around," said
Rounding out the founding executive team as Chief Revenue Officer and Co–Founder is
"KeyLift™ sells itself inside the OR — the surgeons who have used it already know," said
Transaction Structure
- Structure: Asset purchase — Amplio Spine, LLC will acquire the KeyLiftXS™ and KeyLiftXL™ platforms (four sizes each, eight SKUs total), associated IP and patents, FDA 510(k) clearance (K232484), inventory, tooling, customer and distributor relationships, and all related intangible assets.
- Headquarters: Boca Raton,
Florida . - Capital: Amplio Spine is entirely founder–funded; no outside capital has been raised in connection with this transaction.
- Leadership: Josh Lambert, CEO & Co–Founder;
Ryan Dickinson , COO & Co–Founder;Blake Boesel , CRO & Co–Founder. - Expected closing: Q2 2026, subject to definitive documentation and customary closing conditions.
- Financial terms: Not disclosed.
About Amplio Spine, LLC
Amplio Spine, LLC, headquartered in
About FloSpine, LLC
FloSpine, LLC is a
Forward–Looking Statements
This press release contains forward–looking statements regarding a proposed transaction that has not yet closed and the future commercialization of the KeyLift™ family. The Letter of Intent is non–binding and remains subject to due diligence, negotiation and execution of definitive agreements, regulatory considerations, and customary closing conditions. There can be no assurance that the transaction will close on the terms described, on the timeline anticipated, or at all. Forward–looking statements involve known and unknown risks, including competitive, clinical, reimbursement, supply chain, and regulatory risks, that could cause actual results to differ materially from those expressed or implied. Amplio Spine, LLC undertakes no obligation to update or revise any forward–looking statement except as may be required by law.
Media Contact
Amplio Spine, LLC
[email protected] | www.ampliospine.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fdacleared-quietly-adopted-nationally-ready-keylift-is-about-to-get-loud-302750902.html
SOURCE Amplio Spine
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Bybit Card Advantage: Exclusive Pre-Sale Access to Tomorrowland Brasil 2027 Tickets
- North Miami Police Department Deploys Mark43 to Drive Efficiency, Data-Driven Policing, and Safer Communities
- NexPoint Capital, Inc. Announces Tender Offer for Common Stock
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share